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Although the a6b1 integrin has been implicated in
the function of breast and other cancer stem cells
(CSCs), little is known about its regulation and rela-
tionship to mechanisms involved in the genesis of
CSCs.We report that a CD44high/CD24low population,
enriched for CSCs, is comprised of distinct epithelial
and mesenchymal populations that differ in expres-
sion of the two a6 cytoplasmic domain splice vari-
ants: a6A and a6B. a6Bb1 expression defines the
mesenchymal population and is necessary for CSC
function, a function that cannot be executed by
a6A integrins. The generation of a6Bb1 is tightly
controlled and occurs as a consequence of an
autocrine vascular endothelial growth factor (VEGF)
signaling that culminates in the transcriptional
repression of a key RNA-splicing factor. These data
alter our understanding of how a6b1 contributes
to breast cancer, and they resolve ambiguities
regarding the use of total a6 (CD49f) expression as
a biomarker for CSCs.
INTRODUCTION
Most solid tumors, including breast carcinomas, harbor a rela-
tively small population of cells with characteristics of stem cells,
including the ability to self-renew and populate new tumors. This
population is often referred to as tumor-initiating cells or cancer
stem cells (CSCs) (Al-Hajj et al., 2003; Baccelli and Trumpp,
2012; Visvader and Lindeman, 2012). Understanding the biology
of CSCs is highly significant because this population of cells is
likely responsible for tumor recurrence in response to therapy
and it may contribute to metastasis (Calcagno et al., 2010;
Dean et al., 2005; Pinto et al., 2013). A frequent observation is
that high expression of the a6 integrin subunit (CD49f) is a
biomarker for breast and other CSCs (Goel et al., 2013; Meyer
et al., 2010; Vieira et al., 2012). This subunit heterodimerizeswith either the b1 or b4 subunits to generate the a6b1 and
a6b4 integrins, which function primarily as laminin receptors
(Mercurio, 1990). Interestingly, however, the b4 subunit appears
to be expressed at very low levels, if at all, in CSCs compared to
non-CSCs, indicating that a6b1 is the dominant a6 integrin
expressed by CSCs (Goel et al., 2013; Lathia et al., 2010).
Although the a6b1 integrin has been implicated in the function
of breast and other CSCs (Cariati et al., 2008; Goel et al., 2013;
Lathia et al., 2010), much needs to be learned about the contri-
bution of this integrin to the genesis of CSCs. Specifically,
a6b1 is expressed in both differentiated (e.g., luminal) and dedif-
ferentiated breast carcinoma cells (e.g., triple-negative [TPN])
and the relationship between a6b1 and differentiation status is
unclear, especially in the context of CSCs. There are also reports
that high a6b1 expression is not always characteristic of CSCs
(Sarrio et al., 2012). The fact that the a6 integrin exists as two
distinct cytoplasmic domain variants, a6A and a6B, which are
generated by alternative mRNA splicing (Hogervorst et al.,
1991; Tamura et al., 1991), could be relevant to our understand-
ing of the function of this integrin in CSCs, but little is known
about the relative contribution of these variants to self-renewal
and tumor initiation.
This study was prompted by our analysis of the CD44high/
CD24low population of breast cancer cells, a minor population
known to be tumorigenic and enriched for stem cell properties
(Al-Hajj et al., 2003; Azzam et al., 2013; Iliopoulos et al., 2011).
Unexpectedly, we discovered that this population is comprised
of distinct epithelial and mesenchymal populations and that
these populations differ in their expression of the a6A and a6B
integrin subunits. The epithelial population is characterized by
predominantly a6A and very low levels of a6B expression, and
a6B expression predominates in the mesenchymal population.
This observation prompted us to investigate the relevance of
a6A and a6B expression to self-renewal and tumor initiation.
We discovered that the a6Bb1 integrin is the critical a6b1 variant
that drives CSC function in TPN breast cancer and promotes
tumor initiation and that this function cannot be executed by
a6A integrins. Given that splicing regulates the differential
expression of a6A and a6B, we discovered that a6Bb1 expres-
sion is sustained by a vascular endothelial growth factorCell Reports 7, 747–761, May 8, 2014 ª2014 The Authors 747
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Figure 1. Identification of Distinct CD44highCD24low Populations that Differ in Morphology and Stem Cell Properties
(A) MCF-10A ER-SRC cells were treated with 4-hydroxytamoxifen (TAM) and FACS analyzed using CD44, CD24, and a6 (GoH3) antibodies.
(B) The CD44high/CD24low population isolated from TAM-treatedMCF-10A ER-SRC cells was sorted by FACS into two subpopulations based on expression of the
a6 integrin subunit. Photomicrographs of these two subpopulations designated as EPTH (a6 high) andMES (a6 low) are shown. The scale bar represents 100 mm.
(C) Cell extracts from EPTH andMES cells were immunoblotted to assess expression of N-cadherin, E-cadherin, HIF-1a, vimentin, actin, and VEGF-A (left panel).
EPTH and MES cells were immunostained for CK8 and CK18, and the quantitation of positive cells is presented (right panel).
(D) Expression of integrin a6, b1, and b4 mRNAs was quantified in EPTH and MES cells using qPCR.
(E) The CD44high/CD24low population from TAM-treated MCF-10A ER-SRC cells was stained with PKH26 and cultured for 14 days. Cells were analyzed by FACS
for PKH and integrin a6 expression.
(F) Expression of ALDH1A1 and BMI-1 mRNAs was quantified in EPTH and MES cells using qPCR.
(legend continued on next page)
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(VEGF)-signaling pathway that promotes dedifferentiation and
culminates in the repression of a key splicing factor that impedes
the genesis of a6B. These data reveal an integrated pathway that
regulates integrin splicing and the consequent formation of an a6
splice variant necessary for self-renewal and tumor initiation.
RESULTS
Identification of Two Distinct Populations of CD44high/
CD24low Cells that Differ in Stem Cell Properties and
Expression of a6 Integrin Splice Variants
Expression of SRC inMCF-10A cells using a tamoxifen-inducible
ER-SRC construct increases the number of CD44high/CD24low
cells when compared with nontransformed cells (Iliopoulos
et al., 2011). Flow cytometry using an a6-specific antibody (Ab)
revealed two distinct populations of cells within the CD44high/
CD24low population that differ in their relative expression of a6:
populations of relative high and low a6 expression. In contrast,
only the high a6 peak was seen in the other, non-CSC sub-
populations (CD44lowCD24low, CD44highCD24high, and
CD44lowCD24high; Figure 1A). Moreover, SRC transformation
alters the distribution of a6 expression with a shift toward the
a6-low peak (Figure S1A). To gain insight into the nature of these
two a6 populations, we sorted CD44high/CD24low cells with fluo-
rescence-activated cell sorting (FACS) in order to isolate the a6-
high and low cells and characterized them. Surprisingly, these
two populations differed markedly in their morphology. The a6-
low population had a distinct mesenchymal morphology (MES)
compared to the epithelial morphology (EPTH) of the a6-high
population (Figure 1B). Consistent with their morphology,
EPTH cells express more E-cadherin and MES cells express
more N-cadherin, vimentin, hypoxia-inducible factor 1a
(HIF-1a), and VEGF. Cytokeratin 8 and cytokeratin 18, markers
of differentiated secretory epithelia, are enriched in the EPTH
population (Figure 1C). Snai1 and Zeb1, epithelial-mesenchymal
transition (EMT)-associated transcription factors (Nieto and
Cano, 2012), are expressed in the MES population (Figure S1B).
Also, expression of the b4 integrin subunit is high in EPTH cells
and low inMES cells, indicating that EPTH cells express primarily
a6b4 and MES express a6b1 (Figure 1D). We also observed that
EPTH cells are stable and maintain their epithelial nature in
culture but that MES cells slowly transition to epithelial cells
(Figure S1C).
Although the CD44high/CD24low population is considered to
have stem cell properties (Al-Hajj et al., 2003; Azzam et al.,
2013; Iliopoulos et al., 2011), our data indicate that this pop-
ulation is heterogeneous and that the EPTH and MES popula-
tionsmay differ in stem cell characteristics. Indeed, we observed
increased expression of ALDH1 andBMI1, which are established
stem cell markers (Douville et al., 2009; Liu et al., 2006), and
increased retention of PKH, a marker for slow-cycling cells(G) The CD44high/CD24low population isolated from TAM-treated MCF-10A ER-S
surface expression was analyzed by FACS.
(H) TAM- treated MCF-10A ER-SRC cells were FACS sorted into subpopulatio
formation (left panel). EPTH and MES cells were assayed for mammosphere form
(I) EPTH andMES cells (106 cells per mouse) were implanted in the mammary fat p
curve comparison was done using log rank test (p = 0.006).(Pece et al., 2010), in the MES population (Figures 1E and 1F).
To substantiate these results, we treated SRC-transformed
MCF-10A cells with Taxol, which selectively kills growing cells
and enriches for slow-cycling cells (Tanei et al., 2009). Taxol
treatment enriched cells in the first peak of a6 integrin (MES
cells), supporting the hypothesis that these are slow-cycling
cells (Figure 1G). Most importantly, the EPTH and MES cells
exhibited significant differences in their ability to form mam-
mospheres (Figures 1H and S1D) and initiate tumors upon
mammary fat pad implantation in nonobese diabetic
(NOD).Cg-Prkdcscid IL2rgtm1Wjl (NSG) mice (Figure 1I), indicating
that the MES population is enriched for CSCs.
The fact that MES population exhibited reduced a6 integrin
expression but enhanced CSC properties compared to the
EPTH population prompted us to assess the relative expression
of the a6A and a6B splice variants. We observed that EPTH cells
express predominantly a6A and very low levels of a6B and that
a6B is the predominant variant in theMESpopulation (Figure 2A).
Based on this result, we evaluated the relative expression of
these variants in normal (MCF-10A), luminal (T47D and SK-
BR-3), and TPN (MDA-MB-435, MD-MB-231, and SUM1315)
breast cancer cell lines. Normal and luminal cell lines tested
expressed predominantly a6A and TPN cells expressed pre-
dominantly a6B as detected by immunoblotting (Figure 2B).
The a6Bb1 Integrin Promotes the Function of Breast
CSCs, and Its Expression Is Tightly Regulated by
Epithelial Splicing Factor ESRP1
To investigate the relative contribution of the a6Ab1 and a6Bb1
integrins, we used TPN breast cancer lines, which are enriched
with CSCs. Given that these cells predominantly express a6B
but also some a6A, we sought to obtain equivalent surface
expression of a6Ab1 and a6Bb1. Also, it is not possible to design
small hairpin RNAs (shRNAs) that target a6B specifically
because of sequence homology between the two variants. For
these reasons, we used an shRNA that targets the 30 UTR that
is common to both a6A and a6B to deplete the expression of
endogenous a6 integrins, and then we re-expressed either a6A
or a6B (Figures S2A and 2C). The cell lines generated predomi-
nantly express only one of these cytoplasmic variants (Fig-
ure 2C), and these two integrin variants exhibit similar levels of
surface expression (Figure S2B). Cells expressing a6Bb1 had
decreased E-cadherin and increased vimentin expression and
proliferated more slowly compared to cells expressing a6Ab1
(Figures S2C and S2D). Also, compared to cells expressing
either empty vector or a6Ab1, cells expressing a6Bb1 had signif-
icantly more self-renewal ability as measured by mammosphere
serial passage (Figures 2D, S2E, and S2F), more retention of
PKH (Figure S3A), and increased anchorage-independent
growth (Figures 2E and S2G). To test whether tumor cell popula-
tions that express a6Bb1 have a greater number of CSCsRC cells was treated with either Taxol or ethanol for 7 days, and integrin a6
ns based on expression of CD44 and CD24 and assayed for mammosphere
ation (right panel).
ads of NSGmice (n = 12), and tumor formation was assessed by palpation. The
Cell Reports 7, 747–761, May 8, 2014 ª2014 The Authors 749
AC
E
G H I
F
D
B
Figure 2. a6B Cytoplasmic Variant Expression Determines Tumor-Initiating Potential in Breast Cancer Cells
(A) Cell extracts from EPTH and MES were immunoblotted for integrin a6A, a6B, and tubulin.
(B) Cell extracts from breast cancer cell lines were immunoblotted for a6A (left blot) and a6B (right blot).
(C) Integrin a6-depleted SUM1315, MDA-MB-435, andMDA-MB-231 cells were stably transfectedwith either empty vector (EV), a6A, or a6B. Transfectants were
analyzed by immunoblotting using a6A, a6B, or actin Abs.
(D) Mammospheres from SUM1315 transfectants (a6A or a6B) were passaged serially, and the number of mammospheres is presented.
(E) Integrin a6A and a6B transfectants of SUM1315, MDA-MB-435, and MDA-MB-231 cell lines were assessed for growth in soft agar.
(F) Integrina6Aanda6BtransfectantsofSUM1315 (leftpanel) andMDA-MB-435 (rightpanel) cellswere transplanted intomammary fatpadsofNSGmiceusing10-fold
serial dilution. The formationof palpable tumorswas used toevaluate tumor initiation. Data are presented asa log-log plot, and frequency of stemcells is calculatedby
extreme limiting dilution analysis. Red, SUM1315-a6B (1/4,479) or MDA-MB-435-a6B (1/1,425); black, SUM1315-a6A (1/68,078) or MDA-MB-435-a6A (1/37,586).
(G) Expression of a6B was depleted in MDA-MB-231 cells using a6B-specific TALENs in combination with a donor plasmid containing a puromycin expression
cassette, and expression of a6A, a6B, and actin was assessed by immunoblotting.
(H) Mammospheres from the transfectants in G (Puro-alone or TALENs-pool) were passaged serially, and the number of mammospheres is presented.
(I) Soft agar growth from the transfectants in G (Puro-alone, TALENs-pool, TALENs-C1, and TALENs-C2) is presented as themean number of colonies in 20 fields.
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compared to cells that express a6Ab1, we performed limiting
dilution experiments in vivo. As few as 100 cells for MDA-MB-
435-a6B (three out of six mice) and 1,000 cells for SUM1315-
a6B (two out of six mice) were sufficient for tumor initiation,
whereas no tumor formation was observed by the corresponding
number of a6A transfectants. Based on the limiting dilution
assay, the frequency of CSCs was calculated to be approxi-
mately 1/1,425 (MDA-MB-435-a6B), 1/37,586 (MDA-MB-435-
a6A), 1/4,479 (SUM1315-a6B), and 1/68,078 (SUM1315-a6A;
Figure 2F). These data demonstrate that breast cancer cells
expressing a6Bb1 are significantly more enriched in stem cell
properties than cells expressing a6Ab1.
Wemade use of transcription activator-like effector nucleases
(TALENs) to disrupt the alternative splicing site in the a6 integrin
mRNA as a rigorous approach to substantiate the role of a6B
and to circumvent the fact that RNAi cannot be used to target
this splice variant specifically. TALEN-mediated disruption of
the alternative splicing site resulted in markedly reduced a6B
expression and a concomitant increase in a6A expression (Fig-
ure 2G). Importantly, depletion of a6B significantly inhibited
self-renewal (Figure 2H) and colony formation in soft agar
(Figure 2I).
Differential expression of a6A and a6B is determined by
alternative splicing of the a6 subunit, a process mediated by
specific splicing factors (Warzecha et al., 2010). We compared
EPTH and MES cells for the expression of splicing factors
(ESRP1, ESRP2, RBFOX2, andMBNL) that have been implicated
in epithelial differentiation/EMT and CSCs and that could regu-
late a6 splicing (Brown et al., 2011; Shapiro et al., 2011; Yae
et al., 2012; Han et al., 2013). ESRP1 is the only factor that
exhibited a marked difference in expression between the two
populations (24-fold lower in MES compared to EPTH cells; Fig-
ure 3A). The other factors are expressed at low levels in both
populations (Figure 3A). Also, expression of ESRP1 is extremely
low in TPN compared to luminal (MCF7) or normal (MCF-10A)
breast cancer cells (Figure 3B). Based on these observations,
we hypothesized that loss of ESRP1 increases a6B and de-
creases a6A. Indeed, downregulation of ESRP1 in SRC-trans-
formed MCF-10A cells significantly increased a6B and reduced
a6A expression (Figure 3C). Similarly, exogenous expression of
ESRP1 in TPN MDA-MB-435, SUM1315, MDA-MB-231, and
SUM159 cells increased a6A and reduced a6B expression,
and it diminished the ability of these cells to form colonies in
soft agar (Figures 3D, 3E, and S3B). Downregulation of ESRP1
significantly increased the number of soft agar colonies and
self-renewal ability (Figure S3C). Taxol treatment of SRC-trans-
formed MCF-10A cells, which enriches for CSCs (Tanei et al.,
2009), increased a6B expression and reduced expression of
ESRP1 and a6A (Figure 3F). Expression of ESRP1 in TPN cell
lines reduced their self-renewal potential as measured by serial
passaging of mammospheres (Figure 3G).
To assess whether the correlation between a6 integrin variants
and ESRP1 exists in clinical samples from breast cancer
patients, we quantified ESRP1, a6A, and a6B mRNA expression
in TPN and non-TPN breast tumor samples. VEGF expression
was also quantified in the same samples because we previously
reported that VEGF is highly expressed in TPN samples
compared to non-TPN (Goel et al., 2013). As shown in Figures4A and 4B, expression of a6A, as well as ESRP1, is significantly
lower in TPN compared to non-TPN tumors. In contrast, VEGF
and a6B expression is significantly higher in TPN samples. We
also observed that ESRP1 is positively correlated with a6A but
negatively correlated with VEGF and a6B (Figure 4C). We also
immunoblotted tumor samples with an a6B-specific Ab and
observed that a6B is significantly higher in TPN samples (n =
17) compared to non-TPN (n = 18) and its expression is nega-
tively correlated with ESRP1 (Figures 4D–4F).
VEGF/NRP/GLI1 Signaling Suppresses ESRP1 via BMI1
Based on the interesting negative correlation observed in tumor
specimens between VEGF and ESRP1 expression, we investi-
gated the possibility that VEGF signaling suppresses ESRP1
and, consequently, induces a6B expression. Previously, we
reported that autocrine VEGF signaling, mediated through a
neuropilin-2/a6b1 complex, promotes the initiation of TPN
tumors via GLI1 (Goel et al., 2012a, 2013). In support of this
possibility, we observed that cells expressing a6B (MDA-MB-
435, MDA-MB-231, and SUM1315), as well as the MES cells,
exhibited increased expression of VEGF, NRP1, and NRP2
compared to cells expressing a6A and the EPTH cells (Figures
5A and 5B). Inhibition of either VEGF (using small interfering RNA
[siRNA]) or NRP (using an inhibitory peptide c-furSEMA) signifi-
cantly reduced the self-renewal ability of the a6B transfectants
(Figure 5C). Finally, depletion of VEGF caused a significant in-
crease inESRP1anda6Aexpressionbut reduceda6B (Figure5D).
Autocrine VEGF signaling has been shown to induce expres-
sion of GLI1 (Goel et al., 2013), a hedgehog target gene that
has been implicated in the function of CSCs (Fiaschi et al.,
2009; Goel et al., 2013; Liu et al., 2006). Indeed, we observed
increased GLI1 expression in the MES population and a6B
transfectants (Figures 5B and 5E). Importantly, GLI1 expression
is significantly reduced by TALEN-mediated downregulation of
a6B, supporting the role of a6Bb1 in this VEGF/NRP/GLI1-
signaling pathway (Figure 5F). Given that TALEN-mediated
downregulation of a6B increased a6A and decreased GLI1, we
hypothesized that GLI1 may inhibit ESRP1 expression. This
hypothesis is supported by experiments in which we modulated
GLI1 expression in SUM1315 and MCF-10A cells and observed
a significant effect on ESRP1 expression (Figure 5G). We also
detected a negative correlation between ESRP1 and GLI1
expression in a cohort of 310 breast cancer patients (p = 2.2 3
1016; Figure 5H) using cBIOPORTAL (http://cbioprotal.org;
MSKCC). To substantiate the negative regulation of ESRP1 by
GLI1, we analyzed mammary tumors in mouse mammary tumor
virus (MMTV)-GLI1 andMMTV- polyoma virusmiddle T (PyV-MT)
mice. Mammary tumors in MMTV-GLI1 mice have enhanced
expression of VEGF, NRP2, and BMI-1 compared to MMTV-
PyV-MT tumors (Goel et al., 2013).We detected reduced expres-
sion of ESRP1 and a6A and increased expression of a6B in
MMTV-GLI1 compared to MMTV-PyV-MT tumors (Figure 5I).
To investigate how ESRP1 expression is inhibited by GLI1, we
focused on BMI1 because GLI1 promotes breast CSC function
by inducing BMI1 (Goel et al., 2013) and BMI1 functions as a
transcriptional repressor (Bunker and Kingston, 1994; Goel
et al., 2012b). Moreover, expression of GLI1 and BMI1 is signif-
icantly higher in the a6B transfectants and MES cells than in theCell Reports 7, 747–761, May 8, 2014 ª2014 The Authors 751
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Figure 3. ESRP1 Promotes Integrin a6A Expression
(A) Expression of ESRP1, ESRP2, RBFOX2, and MBNL1 mRNAs was quantified in EPTH and MES cells using qPCR.
(B) Expression of ESRP1 mRNA was quantified in breast cancer cell lines using qPCR.
(C) ESRP1was downregulated inMCF-10A cells, and cell extracts were immunoblotted to assess the expression of integrin subunits a6A, a6B, ESRP1, and actin.
(D) The effect of ESRP1 on a6B and a6A expression, as assessed by immunoblotting (left panels), or on the ability of breast cancer cell lines to form colonies in soft
agar (right panel).
(legend continued on next page)
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a6A transfectants and EPTH cells (Figures 6A and S4A). Exo-
genous expression of a6B in MCF7 cells increased GLI1
(Figure S4B) and BMI1 (Figure 6B), as well as their self-renewal
ability and other established markers of stemness (Figures S4B
and S4C). Expression of BMI1 in MCF-10A cells suppressed
ESRP1 and a6A expression but increased a6B expression (Fig-
ure 6C). Conversely, downregulation of either BMI1 or GLI1 in
MDA-MB-435 cells increased ESRP1 and a6A expression but
reduced a6B expression (Figure 6D). We performed chromatin
immunoprecipitation (ChIP) to assess BMI1 binding to the
ESRP1 promoter and observed binding to specific sequences
within this promoter (Figure 6E). Self-renewal ability mediated
by a6Bb1 is dependent upon BMI1 because BMI1 downregula-
tion inhibits the ability of a6B transfectants to form mammo-
spheres in serial passage (Figure 6F). Finally, a negative correla-
tion between BMI1 and ESRP1 was observed in our analysis of
the human breast cancer data set described above (Figure 6G).
Collectively, our data indicate that autocrine VEGF signaling
controls the splicing of the a6 integrin subunit by a mechanism
that involves GLI1-mediated induction of BMI1 and BMI1-medi-
ated repression of ESRP1. To validate this mechanism, we engi-
neered MDA-MB-231 to express GFP under control of the VEGF
promoter. FACS analysis revealed a small population of GFP+
cells (1%) that expresses significantly higher levels of VEGF
in comparison to the bulk population (Figure 7A). We isolated
these populations and assessed their properties. These VEGF-
high cells grow much more slowly (data not shown) and are
more resistant to Taxol than the bulk population (Figure S5A).
VEGF-high cells are unstable in culture, and they slowly become
a mixture of VEGF-high and VEGF-low cells. In contrast, the
VEGF-low population does not change in culture (data not
shown). VEGF-high cells form more colonies in soft agar
compared to VEGF-low cells, and colony formation is inhibited
by VEGF downregulation in these cells (Figures 7B and S5B).
VEGF-high, but not VEGF-low cells, are sensitive to VEGF and
NRP inhibitors (Figure S5C), establishing the validity of this
model system. Tumor onset upon orthotopic fat pad implanta-
tion, as well as self-renewal assays, indicate that VEGF-high
cells are enriched for CSCs compared to VEGF-low cells (Fig-
ures 7C and 7D). Consistent with these findings, VEGF-high cells
express high levels of a6B, NRPs, GLI1, and BMI1 but reduced
levels of a6A and ESRP1 (Figures 7E and 7F). Finally, expression
of ESRP1 in VEGF-high cells increased a6A expression (Fig-
ure 7G) but reduced self-renewal ability in vitro and tumor onset
in vivo (Figures 7H and 7I). VEGF/GLI1 signaling also promotes
chemoresistance because VEGF downregulation and GLI1 inhi-
bition increased sensitivity to Taxol (Figure S5D).
DISCUSSION
This study revealed that the contribution of the a6b1 integrin to
the function of breast CSCs is not dependent on its level of(E) The effect of ESRP1 expression on ESRP1 (left panels), integrin a6A expre
using qPCR.
(F) The CD44high/CD24low population from TAM-treated MCF-10A ER-SRC cells w
and ESRP1 was analyzed by immunoblotting.
(G) The effect of ESRP1 expression on self-renewal ability was analyzed by seriaexpression as often assumed but rather on the relative expres-
sion of a specific splice variant of this integrin, a6Bb1.
Conversely, the a6A integrins lack the ability to promote breast
CSC function. The importance of a6Bb1 is highlighted by our
discovery that expression of the a6B subunit is repressed by
the ESRP1-splicing factor and intimately associated with a
VEGF autocrine signaling pathway that sustains CSCs and
promotes tumor initiation. The fact that a6Bb1 initiates a
signaling pathway that sustains its expression argues for the
existence of a feedforward loop involved in tumor initiation that
has the a6Bb1 splice variant at its nexus.
A major conclusion of this study is that the a6A and a6B
cytoplasmic domains differ completely in their contribution to
the function of CSCs. The realization that the a6 integrin subunit
exists as two distinct variants that differ only in their cytoplasmic
domains was made more than 20 years ago (Hogervorst et al.,
1991; Tamura et al., 1991). Early studies focused primarily on
correlating a6A and a6B expression with specific cell types
and developmental stages (Hierck et al., 1993; Hogervorst
et al., 1993). Interestingly, oncogenic transformation of keratino-
cytes was observed to increase a6B expression, but the func-
tional consequences were not investigated (Tennenbaum et al.,
1995). Mice that lack a6A, generated by removing the exon
that encodes its cytoplasmic domain, developed normally and
were characterized primarily by defects in lymphocyte migration
(Gimond et al., 1998). More recently, a6A has been implicated in
the proliferation of colon carcinoma cells (Groulx et al., 2014).We
observed that downregulation of a6A did not impact mammo-
sphere formation or a6B expression (Figure S5E). Together,
these results support our hypothesis that a6B is the splice
variant that is critical for slow-cycling stem cell function. In this
context, it is worth noting that a6B expression had been associ-
ated with embryonic stem cells (Cooper et al., 1991; Tamura
et al., 1991), but its functional contribution was not pursued. A
major hindrance to the functional analysis of a6B had been the
lack of an approach to target this variant specifically. RNAi is
not feasible because of sequence homology between a6A and
a6B. Specific function-blocking antibodies do not exist and
could be difficult to generate. Wewere successful in circumvent-
ing these issues using gene-editing TALENs directed at the
alternative splice site in the a6 subunit. This approach enabled
us to inhibit a6B expression specifically and establish its contri-
bution to CSCs.
Our data infer that a6Bb1-mediated signaling is distinct from
other a6 integrin signaling because it can promote the function
of CSCs. This conclusion is supported by the finding that only
a6Bb1 has the ability to induce GLI1 and inhibit ESRP1 transcrip-
tion. Interestingly, a6Bb1 is a component of a VEGF signaling
pathway that represses a6A and sustains a6B expression as
evidenced by the fact that TALEN-mediated knockdown of
a6B increases a6A expression and our previous finding that an
a6b1/NRP2 complex mediates VEGF signaling (Goel et al.,ssion (middle panel), or integrin a6B expression (right panel) was analyzed
as treated with either Taxol or ethanol for 7 days, and expression of a6B, a6A,
l passage of mammospheres.
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Figure 4. ESRP1 and Integrin a6A Expression Is Low in Triple-Negative Tumors and Negatively Correlated with Integrin a6B and VEGF
(A)Frozenclinical specimens fromTPN(n=20)andnon-TPN (n=36)breast tumorswereused tocompareESRP1, integrina6A, integrina6B,andVEGF-165byqPCR.
(B) Graph depicts the fold change in mRNA levels between the TPN and non-TPN specimens shown in (A).
(C) Correlation graphing reveals a significant positive correlation between a6A and ESRP1 expression (left panel), a significant negative correlation between
VEGF-165 and ESRP1 expression (middle panel), and a significant negative correlation between a6B and ESRP1 expression (right panel).
(D) Frozen clinical specimens from TPN (n = 17) and non-TPN (n = 18) breast tumors were used to compare expression of integrin a6B by immunoblotting.
(E) Densitometric analysis of the immunoblot shown in (D).
(F) Correlation graphing reveals a significant negative correlation in the expression of integrin a6B and ESRP1.
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Figure 5. VEGF/NRP2/GLI1 Signaling Represses ESRP1 Expression and Promotes Integrin-a6Bb1-Mediated Self-Renewal
(A) VEGF-A, NRP1, and NRP2 mRNA expression was quantified by qPCR in breast cancer cell lines expressing integrin a6A or a6B variants.
(B) EPTH and MES populations were analyzed for VEGF-A, NRP1, NRP2, or GLI1 mRNA expression using qPCR.
(C) SUM1315-a6B transfectants were depleted of VEGF and NRP using either VEGF siRNA or NRP inhibitors, and these cells were assayed for their ability to be
passaged serially as mammospheres. The number of mammospheres observed at passage 4 is shown.
(D) VEGF was depleted in SUM1315 cells, and the expression of VEGF, GLI1, ESRP1, a6A, a6B, and actin was assessed by immunoblotting.
(E) Cell extracts from SUM1315 transfectants (EV, a6A, or a6B) were immunoblotted with Abs specific to GLI1, ESRP1, and actin.
(F) Expression of a6B was depleted in MDA-MB-231 cells using a6B-specific TALENs, and expression of GLI1 and actin was assessed by immunoblotting.
(legend continued on next page)
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Figure 6. BMI1 Suppresses ESRP1 and Controls a6Bb1-Mediated Self-Renewal
(A) Extracts from a6A- or a6B-expressing breast cancer cells were immunoblotted with Abs to GLI1, BMI1, and actin.
(B) MCF-7 cells expressing either EV, a6A, or a6B were analyzed for expression of a6A, a6B, BMI1, and actin.
(C) BMI1 was expressed in MCF-10A cells, and its effect on a6A, ESRP1, and a6B expression was assessed by qPCR.
(D) Downregulation of BMI1 or GLI1 significantly increased ESRP1 and a6A but reduced a6B mRNA levels.
(E) Binding of BMI1 on the ESRP1 promoter was analyzed using ChIP. Primers P2 and P3, which span the region1,422 to1,802 upstream of the transcription
start site of ESRP1, show significant binding of BMI1. IgG, immunoglobulin.
(F) Effect of BMI1 downregulation on the self-renewal potential of a6B transfectants is shown at mammosphere passages 3 and 4.
(G) A significant negative correlation between expression of BMI1 and ESRP1 was observed in breast cancer patient cohorts.2013). Also, a6B is the predominant variant observed in cells that
exhibit autocrine VEGF/NRP2 signaling. These findings are
significant because they provide a mechanism for how a6B
expression is regulated in cancer. The limited data published
on the a6 splice variants do not address how they are regulated
differentially, especially in a pathophysiological context. In
essence, our data support the existence of a feedforward(G) Cell extracts from SUM1315 cells expressing either GFPsh or GLI1sh were imm
MCF-10A cells were transfected with GLI1 and analyzed for expression of GLI1,
(H) A significant negative correlation between GLI1 and ESRP1 expression was o
(I) Expression of ESRP1, a6A, and a6B is compared between MMTV-PyV-MT an
756 Cell Reports 7, 747–761, May 8, 2014 ª2014 The Authorssignaling loop that involves a6Bb1 and that functions to sustain
a6B and repress a6A expression. Interestingly, a contribution
of a6Bb4 to this signaling pathway and the function of CSCs
is not supported by our data despite the fact that a6b4 integrin
has been implicated in breast cancer formation and progression
(Guo et al., 2006; Lipscomb et al., 2005; Shaw et al., 1997).
The MES population of CD44high/CD24low SRC-transformedunoblotted using Abs to GLI1, ESRP1, a6A, a6B, BMI1, and actin (left panels).
a6A, a6B, ESRP1, and actin (right panel).
bserved in breast cancer patient cohorts.
d MMTV-GLI1 mouse tumor models.
AD
F
H I
G
E
B C
Figure 7. Integrin a6Bb1 Is at the Nexus of a Feedforward VEGF-Signaling Loop that Sustains Self-Renewal and Tumor Initiation
(A) FACS profile of MDA-MB-231 cells stably expressing GFP under control of the VEGF promoter is shown.
(B) Freshly sorted VEGF-high or VEGF-low populations were used to measure colony formation in soft agar.
(C) VEGF-high or VEGF-low cells were implanted in the mammary fat pad of NSG mice (n = 8), and tumor formation was assessed by palpation. The curve
comparison was done using log rank test (p = 0.008).
(D) The effect of VEGF expression on self-renewal ability was analyzed by serial passage of mammospheres.
(E) Expression of key signaling proteins in VEGF-high and VEGF-low cells was quantified by qPCR.
(legend continued on next page)
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MCF-10A cells, which has stem cell properties, expresses very
little b4 compared to the EPTH population (Figure 1D). This
observation is consistent with the finding that b4 expression is
repressed during the EMT (Yang et al., 2009). Moreover, late-
passage mammospheres, which are enriched for CSCs, lack
detectable b4 expression despite the fact that adherent cultures
of the same cells express b4 (Figure S5F). The intriguing issue
that arises from these observations is the mechanism by which
a6b4 contributes to breast cancer formation (Guo et al., 2006;
Lipscomb et al., 2005).
We conclude that the CD44high/CD24low population of cells
enriched for CSCs in TPN breast cancer is actually comprised
of distinct epithelial andmesenchymal subpopulations that differ
markedly in stem cell properties and tumor-initiating potential. In
this direction, a recent study observed heterogeneity in the
tumor-initiating population of TPN breast cancer based on the
level of CD24 expression (Azzam et al., 2013), substantiating
the complexity of putative CSC populations and the need for
more specific biomarkers. Our findings also bear on the current
debate regarding the role of epithelial differentiation in the
genesis of CSCs. Epithelial dedifferentiation and the EMT have
been shown to have a causal role in the genesis of CSCs (Scheel
et al., 2011; Scheel and Weinberg, 2012), and our data support
the involvement of a6Bb1 in this process. Nonetheless, recent
studies have challenged this hypothesis and proposed that
stem cell properties reside in an epithelial population (Ocan˜a
et al., 2012; Sarrio et al., 2012). An advantage of our approach
is that we were able to compare differentiated and dedifferenti-
ated cells within the same population of cells enriched for stem
cell makers and determine that their stem cell properties are
manifested primarily in the dedifferentiated cells that are charac-
terized by a high ratio of a6B/a6A and expression of mesen-
chymal markers. Nonetheless, the epithelial subpopulation of
CD44high/CD24low cells harbors some stem cell properties as
evidenced by the data in Figure 1I, and we are intrigued by the
possibility that this population may facilitate the function of the
mesenchymal population. It is also worth noting that CSC prop-
erties differ among cancers and cancer subtypes (Visvader and
Lindeman, 2012) and that our findings are relevant to TPN breast
cancer.
We conclude from our data that autocrine VEGF signaling
promotes CSC function by regulating the expression of splicing
factors that contribute to posttranscriptional gene regulation.
This conclusion establishes a connection between autocrine
growth factor signaling and RNA splicing. Our data also impact
the emerging importance of alternative RNA splicing to the
EMT and stem cell biology (Brown et al., 2011; De Craene and
Berx, 2013; Han et al., 2013; Shapiro et al., 2011; Warzecha
et al., 2010; Yae et al., 2012). Epithelial cells harbor a complex,
alternative splicing network that contributes to the expression
of splice variants of key proteins that sustain the epithelial(F) Expression of VEGF, a6A, and a6B in VEGF-high and low populations was ass
levels of a6A compared to the VEGF-low population.
(G) ESRP1 expression in the VEGF-high population increases a6A mRNA expres
(H) Effect of ESRP1 expression on the self-renewal ability of VEGF-high cells wa
(I) Effect of ESRP1 expression in VEGF-high cells on tumor onset was analyzed by
(n = 8). The curve comparison was done using log rank test (p = 0.02).
758 Cell Reports 7, 747–761, May 8, 2014 ª2014 The Authorsphenotype (Warzecha et al., 2010). The regulated expression
of splicing factors such as the ESRPs enables the expression
of specific splice variants in epithelial cells. Alterations in the
expression of splicing factors can disrupt epithelial splicing,
resulting in an EMT (Brown et al., 2011; Shapiro et al., 2011; War-
zecha et al., 2010) and contributing to the genesis of CSCs (Yae
et al., 2012). An important observation from our perspective is
that loss of ESRP1 expression, which occurs during the EMT,
causes an increase in a6B and a decrease in a6A expression,
a finding that implicates this splicing factor in the genesis of
a6Bb1 (Warzecha et al., 2010). More specifically, it has been
shown that ESRP1 binds to a specific UGG-rich recognition
motif in the a6 mRNA and promotes exon inclusion to generate
a6A (Warzecha et al., 2010). Loss of ESRP1 results in the deletion
of this exon from the mature mRNA and the consequent gener-
ation of a6B and diminution of a6A. The importance of our
work is that we established that autocrine VEGF signaling
sustains BMI1-mediated repression of ESRP1 and the conse-
quent increase in a6B and decrease in a6A expression. This
finding is significant because it establishes an integrated
signaling pathway that regulates integrin splicing. Also, autocrine
VEGF signaling is emerging as a critical pathway that drives CSC
function and tumor initiation, but the mechanisms involved are
still being elucidated (Beck et al., 2011; Goel et al., 2012b,
2013; Goel and Mercurio, 2013; Lichtenberger et al., 2010).
Clearly, the involvement of RNA splicing adds a dimension to
the mechanism by which autocrine VEGF signaling contributes
to tumor initiation.
We propose that the ratio of a6B to a6A integrin subunit
expression is more indicative of stem cell phenotype than total
a6 expression, at least for TPN breast cancer. This conclusion
is timely and significant for several reasons. Although high a6
(CD49f) expression is often used as a marker to identify breast
and other CSCs (Cariati et al., 2008; Lathia et al., 2010; Meyer
et al., 2010; Vieira et al., 2012), other studies on breast CSCs
have observed a decrease in a6 expression (Vaillant et al.,
2008). Based on our findings, we suggest that this discrepancy
reflects differences in the relative expression of a6A and a6B.
In fact, we observed a marked decrease in overall a6 expression
in the MES population of CD44high/CD24low cells compared to
the EPTH population (Figure 1D) but a significant increase in
a6B. Given the heterogeneity that exists within CSC populations
based on our studies and others (Azzam et al., 2013), a6B
expression could be used as a biomarker to define CSCs more
rigorously. The translational impact of our findings could be
significant. High a6B expression in primary tumors could be
prognostic for poor outcome and it could also be used tomonitor
the efficacy of therapy in patients with TPN breast cancer.
Finally, therapeutic approaches that target the splicing proteins
involved in the genesis of a6B or the signaling pathway that
sustains its expression could be effective for the treatment ofessed by immunoblotting. VEGF-high cells express high levels of a6B and low
sion as measured by qPCR.
s analyzed by serial passaging of mammospheres.
transplanting transfectants (105 cells/mouse) inmammary fat pads of NSGmice
TPN and other drug-resistant breast cancers that are enriched
with CSCs (Calcagno et al., 2010).
EXPERIMENTAL PROCEDURES
Reagents and Antibodies
Matrigel was purchased from BD Biosciences; Taxol and 4-hydroxytamoxifen
(TAM) were purchased from Sigma-Aldrich. The following Abs were used: a6
(AA6A, provided by Anne Cress; GoH3, purchased from Millipore); a6A
(1A10; Millipore); a6B (6B4; Millipore); N-cadherin (Invitrogen); E-cadherin
(Invitrogen); tubulin (Sigma-Aldrich); HIF-1a (Novus Biologicals); ESRP1
(Sigma-Aldrich); actin (Sigma-Aldrich); tubulin (Sigma-Aldrich); hemagglutinin
(HA) (Roche); GLI1 (Cell Signaling); BMI-1 (Cell Signaling); cytokeratin 8/cyto-
keratin 18 (Novacastra); phycoerythrin-conjugated anti-CD44 (BD Biosci-
ence); Alexa Fluor 647 anti-CD24 (BD Bioscience); and VEGF (Calbiochem).
A NRP-blocking peptide (c-furSEMA) was provided by Dr. C. Vander Kooi
(University of Kentucky), and bevacizumab was obtained as described (Goel
et al., 2013).
Primary Breast Tumors
Human breast tissues were obtained in compliance with the Institutional
Review Board of the University of Massachusetts Medical School. Snap-
frozen tumors were homogenized to isolate either RNA or protein. For quanti-
tative PCR (qPCR), RNA was isolated using RNeasy kit (QIAGEN) and
converted to cDNA using Transcriptor First Strand cDNASynthesis kit (Roche).
We performed qPCR with a SYBR Green PCR master mix using an ABI Prism
7900HT instrument (Applied Biosystems). Sequences for primers used are
provided in Figure S6. Tumor extracts were also immunoblotted to detect
expression of a6B integrin or actin.
Cells
SUM1315 and SUM159 cells were provided by Dr. Steve Ethier (Medical
College of South Carolina). MCF-10A cells were obtained from the Barbara
Ann Karmanos Cancer Institute. ER-SRC-transformed MCF-10A cells were
provided by Dr. Kevin Struhl (Harvard Medical School). MDA-MB-231, MDA-
MB-435, MCF7, SK-BR-3, and T-47D cells were obtained from American
Type Culture Collection.
Molecular Reagents
Lentiviral constructs containing shRNAs specific for a6 integrin
(TRCN0000296162), GLI1 (TRCN0000020484), ESRP1 (TRCN0000240875),
or GFP (RHS4459) were obtained from Open Biosystems. An siRNA–
SMARTpool to ESRP1 (L-020672-01-0005) was purchased from Thermo
Fisher Scientific. A lentiviral plasmid (FUGW) expressing BMI-1 was obtained
from Addgene. HA-ESRP1 constructs were provided by Dr. Chonghui Cheng
(Northwestern University). pRC-a6A or a6B plasmids were prepared as
described (Shaw et al., 1993) and subcloned into the lentiviral vector pCDH.
A wild-type GLI1 construct was provided by Dr. JunhaoMao (UMASSMedical
School). TALENs that target the splicing site for a6B were designed by the
UMASS Core facility. The donor plasmid was prepared by cloning 500 bp
upstream of the TALENs target site (left arm) followed by SV40 enhancer
plus promoter fragment, puromycin coding sequence, and then 500 bp down-
stream of the TALENs target site (right arm). Upon recombination, the puro-
mycin gene along with its promoter plus enhancer region were inserted at
the a6B-splicing site. The sequence of TALENs is provided in Figure S6. We
used an obligate heterodimer vector to avoid hits to the tal1-tal1 or tal2-tal2
sites. The plasmid expressing GFP under VEGF-A promoter was constructed
by replacing the CMV promoter from pEGFP-N1 vector with the promoter re-
gion (2,414 to 79) of human VEGF-A in the forward direction.
Cell-Based Assays
Flow cytometry was used to analyze surface expression of the a6 integrin,
CD44, and CD24 in breast cancer cell lines. PKH-26 staining was performed
as per manufacturer’s instructions (Sigma). Mammosphere and ChIP assays
were performed as described (Goel et al., 2012b, 2013). ChIP experimentswere performed at least thrice, and the variation was less than 20%. The
primers used to amplify the ESRP1 promoter are provided in Figure S6.
Immunoblotting and qPCR
Cells were extracted in either a Triton X-100 buffer (1% Triton X-100, 150 mM
NaCl, 50 mM Tris-HCl [pH 7.5], 1 mM phenylmethanesulfonylfluoride [PMSF],
and protease inhibitors) or RIPA (50mMTris-HCl [pH 7.4], 150mMNaCl, 0.1%
SDS, 0.5% sodium deoxycholate, 1 mM PMSF, and protease inhibitors). The
proteins were separated by SDS-PAGE and immunoblotted using Abs as
specified in the figure legends. For qPCR, RNA was isolated and qPCR was
performed. Sequences for primers used are provided in Figure S6. Primers
for a6B mRNA quantitation were custom synthesized as described (Groulx
et al., 2014).
Xenograft Experiments
MDA-MB-435 or SUM1315 transfectants expressing a6A or a6B were mixed
with Matrigel at a 10-fold dilution and injected into a mammary fat pad of
immunocompromised NSG mice. Tumor onset was determined by palpation.
In some experiments, cells (106) were injected into a mammary fat pad of NSG
mice and tumor onset was determined by palpation.
Transgenic Mice
MMTV-PyV-MT mice transgenic for the PyV-MT antigen under the control of
the MMTV promoter (Jackson Laboratory) were generated as described
(Nagle et al., 2004). The MMTV-GLI1 transgenic mouse model was generated
previously (Fiaschi et al., 2009). These mice express transgenic GLI1 in the
presence of doxycycline, which was added to drinking water with 5% sucrose.
RNAwas isolated from the tumors collected from thesemice. All animal exper-
iments were in accordance with institutional guidelines and are approved by
Institutional Animal Care and Use Committees.
Statistical Analysis
Statistical analysis (mean, Student’s t test, correlation, and ANOVA) was
performed with R version 3.0.1 (Figure S7).
SUPPLEMENTAL INFORMATION
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